TickerTalks
Browse all tickers →
TickerTalks›$IQV
IQIQV

IQVIA Holdings Inc.

$IQV·$45B·Medical - Diagnostics & Research·Healthcare
$269.19-0.7%YTD+19.4%1Y+49.9%
Price updated 1h ago·X counts updated 2d ago
IQIQV
$IQVIQVIA Holdings Inc.
$269.19-0.66%32 posts0.9×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $IQV on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

32X posts · last 7 days
Sep 11Sep 27
Chatter Meter
0.9×
QuietNormal · 1×Loud

How loud $IQV's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data7 posts analyzed · as of 2026-08-04

IQVIA's Q2 print was a beat-and-guide-in-line — EPS $3.15 vs $3.03 (+$0.12), revenue beat with guidance raised on the back of stronger R&D bookings. IQV is being pitched as one of four public companies with the biggest collections of anonymized healthcare data (alongside UNH, VEEV and TEM). MEDP is being called a positive read-through for IQV within the CRO/tools basket. There's no bearish voice in this window.

Read what X is saying about $IQV

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $IQV — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersAcceleratingAI verdict · as of 2026-09-29

The move is getting stronger, with heavier trading behind it.

IQVIA is up 20% year-to-date and 50% over twelve months on R&D-bookings acceleration and healthcare-data optionality — the CRO leader is being re-rated.

IQVIA is a $44.5B-cap contract-research organization and healthcare-data platform whose operating results have quietly re-accelerated.

  • Up 20% year to date and 50% over the last twelve months, at 95% of its 52-week range and 32% above the 200-day moving average.
  • Q1 revenue $4.15B grew 8% year over year at 33% gross margin and 12% operating margin, EPS $1.63 and $618M of free cash flow.
  • Q4 revenue $4.36B grew 10% year over year — the sequential acceleration is intact.
  • Trailing P/E 22, ROE 22%, and free-cash-flow yield 9% — reasonable multiples for a compounder with genuine data-moat.
  • Three straight beats of 1-4% surprise magnitude — steady, unspectacular beat cadence that matches the tape's grind higher.
  • Positioned as one of the four public companies with the largest anonymized healthcare data assets (alongside UNH, VEEV, TEM).
  • Analyst-covered next-year consensus is $12.97 EPS on $17.4B revenue — implying continued high-single-digit growth.

November 3 earnings will show whether R&D bookings continue to lift the top line and whether the healthcare-data mix expands margin further.

Agrees with X sentimentThe X sample cites the Q2 beat-and-raise, the R&D bookings acceleration, and the healthcare-data optionality — that matches what the fundamentals show.

What to watch: November 3 print — R&D bookings trend, tech-and-analytics segment growth, and any updated FY guide direction.

On the calendar: 2026-11-03 — Q3 earnings

beta missing

Read the AI verdict on $IQV

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Provides healthcare data analytics, clinical trial management, and technology services to life sciences companies globally.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $IQV.

Medical - Diagnostics & Research · Healthcare

Genetic testing, liquid biopsy, and multi-cancer early detection (MCED) platforms are growing through direct-to-consumer and employer wellness channels; reimbursement coverage expansion by CMS and commercial payers is the adoption bottleneck. Lab volume normalization post-COVID is complete; growth is now driven by novel test launches and test menu expansion for chronic disease management.

What this means for $IQV

Partial — Provides healthcare data analytics, clinical trial management, and technology services to life sciences companies globally.

Industry benchmark

18-name peer basket
+46.5%YTD
+79.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
22.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
8.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
13.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
8.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
22.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
26.1%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 28, 2026$3.15$3.03+4.0%
Q1 2026May 5, 2026$2.90$2.82+2.8%
Q4 2025Feb 5, 2026$3.42$3.40+0.6%
Q3 2025Oct 28, 2025$3.00$2.98+0.7%
Next earningsTue, Nov 3·consensus EPS $3.25

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$4.2B+8.4%32.6%12.4%$1.63$618.0M
Q4 FY25$4.4B+10.3%6.7%16.8%$3.02$561.0M
Q3 FY25$4.1B+5.2%33.5%13.5%$1.94$1.2B
Q2 FY25$4.0B+5.3%32.9%12.6%$1.55$292.0M

Forward consensus

5-year forecast · up to 14 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$17.4B$17.4B – $17.5B$12.97$12.92 – $13.0314
FY27$18.4B$18.2B – $19.0B$14.42$13.95 – $15.0614
FY28$19.5B$19.2B – $20.7B$16.15$14.03 – $18.6713
FY29$20.8B$20.6B – $21.3B$18.31$18.12 – $18.9111
FY30$22.2B$22.1B – $22.8B$20.78$20.56 – $21.466

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.95%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+8.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+31.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 156.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 2James G. BerkshireSee Remarks2.7K sh$697KSellAug 3Staub W RichardSee Remarks5.5K sh$1.3MSellJul 31Bhavik PatelSee Remarks1.9K sh$436KSellJul 29Eric SherbetSee Remarks5.0K sh$1.2MSellJul 29Keriann CherofskySee Remarks558 sh$137KSellJul 29Ari BousbibSee Remarks106.3K sh$26.1M
+ 20 other (16 awards · 2 exempts · 2 returns) in window

See when $IQV insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementSep 238-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation
AI summary

IQVIA Inc., a wholly owned subsidiary of IQVIA Holdings (IQV), completed the issuance of $2.0 billion in 6.375% senior unsecured notes due March 15, 2034 on September 23, 2026. Net proceeds will be used to redeem the existing 5.000% Senior Notes due 2026 in full, repay a portion of the revolving credit facility, and cover offering expenses. This is an accretive debt refinancing extending maturity from 2026 to 2034, though the 6.375% coupon is higher than the 5.000% notes being retired, modestly increasing near-term interest expense.

8-KMaterial agreementJun 118-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation
AI summary

IQVIA Inc. (a wholly owned subsidiary of IQVIA Holdings Inc.) completed the issuance of €950 million (~$1.04B) in 4.625% senior unsecured notes due June 15, 2033, on June 11, 2026. The notes are guaranteed by certain IQVIA subsidiaries; interest is payable semi-annually beginning December 15, 2026. Net proceeds will be used to refinance existing indebtedness and pay transaction fees. This is a euro-denominated refinancing that extends IQVIA's debt maturity profile at a moderate fixed rate, consistent with prior capital-structure management for a large healthcare data and analytics company.

8-KOfficer or director changeApr 238-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

IQV disclosed a personnel change (8-K Item 5.02, dated 2026-04-23). An executive departure and a new appointment are both reported. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

+ 10 other (4 routine 8-Ks · 2 10-Qs · 2 earnings 8-Ks · 1 13G) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

IQVIA (NYSE:IQV) Sets New 52-Week High – Time to Buy?defenseworld.net·5d agoContrasting IQVIA (NYSE:IQV) and Bullfrog AI (NASDAQ:BFRG)defenseworld.net·9d agoIQVIA Stock Rises 60% in 6 Months: Here's What You Should Knowzacks.com·14d agoWhy IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Termzacks.com·19d agoArizona State Retirement System Buys 2,372 Shares of IQVIA Holdings Inc. $IQVdefenseworld.net·20d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight LossAI Precision Medicine

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$NEO$A$GRAL$NTRA$ILMN$TMO$DHR$GH
Voices on X · last 7 days

No standout posts about $IQV on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport